Streptococcal pyrogenic exotoxin A (SpeA)

Streptococcal pyrogenic exotoxin A (SpeA) is a potent superantigen secreted by Streptococcus pyogenes (Group A Streptococcus) [1, 3]. It is a primary virulence factor responsible for the severe manifestations of invasive streptococcal infections, including scarlet fever and streptococcal toxic shock syndrome (STSS) [3, 5]. SpeA functions by cross-linking major histocompatibility complex (MHC) class II molecules on antigen-presenting cells with the variable β-chain (Vβ) of T-cell receptors [3, 4]. This interaction bypasses conventional antigen processing, leading to the polyclonal activation of a large fraction of the T-cell repertoire and a subsequent cytokine storm characterized by high levels of TNF-α, IL-1, and IFN-γ [4, 5]. This systemic inflammatory response results in capillary leak, hypotension, and multi-organ failure [5, 10]. Clinically, SpeA is a target for neutralization by intravenous immunoglobulin (IVIG) and for suppression by protein synthesis inhibitors like clindamycin or linezolid [2, 10]. Research is also exploring SpeA-based vaccines and its potential use in targeted cancer immunotherapy [12, 16].

Other names

SpeAErythrogenic toxin AScarlet fever toxin AScarlatina toxin ABlastogen A

Therapeutic strategies involve the neutralization of the toxin by intravenous immunoglobulin (IVIG) and the inhibition of toxin production using protein synthesis inhibitors such as clindamycin and linezolid.